Analysts Set Nuvation Bio Inc. (NYSE:NUVB) PT at $10.80

Nuvation Bio Inc. (NYSE:NUVB) has been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $11.00.

A number of research analysts have recently commented on the stock. Citizens Jmp upped their price objective on shares of Nuvation Bio from $8.00 to $10.00 and gave the company a “market outperform” rating in a research note on Thursday, November 20th. JMP Securities set a $10.00 price target on shares of Nuvation Bio in a research report on Thursday, November 20th. Truist Financial set a $13.00 price target on Nuvation Bio in a report on Tuesday. HC Wainwright lowered their price target on shares of Nuvation Bio from $18.00 to $17.00 and set a “buy” rating for the company in a report on Monday, January 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $6.00 target price on shares of Nuvation Bio in a research report on Monday, October 13th.

Insider Activity

In other Nuvation Bio news, insider Dongfang Liu sold 150,000 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $7.82, for a total transaction of $1,173,000.00. Following the completion of the transaction, the insider directly owned 18,000 shares of the company’s stock, valued at $140,760. This trade represents a 89.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 220,000 shares of company stock valued at $1,548,800 in the last three months. 29.93% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Nuvation Bio by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 15,555,606 shares of the company’s stock valued at $139,378,000 after acquiring an additional 101,011 shares during the last quarter. Geode Capital Management LLC increased its stake in Nuvation Bio by 16.8% during the second quarter. Geode Capital Management LLC now owns 5,994,798 shares of the company’s stock valued at $11,691,000 after purchasing an additional 864,194 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Nuvation Bio by 52.4% during the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock worth $6,642,000 after purchasing an additional 1,298,131 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Nuvation Bio by 19.9% during the third quarter. Dimensional Fund Advisors LP now owns 3,321,249 shares of the company’s stock worth $12,276,000 after purchasing an additional 551,508 shares during the period. Finally, Aisling Capital Management LP lifted its position in shares of Nuvation Bio by 16.5% in the 3rd quarter. Aisling Capital Management LP now owns 2,960,659 shares of the company’s stock worth $10,954,000 after buying an additional 419,650 shares during the last quarter. Institutional investors own 61.67% of the company’s stock.

Nuvation Bio Stock Performance

NYSE:NUVB opened at $5.34 on Friday. The firm has a market cap of $1.83 billion, a PE ratio of -8.35 and a beta of 1.54. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.48 and a quick ratio of 8.39. Nuvation Bio has a 1-year low of $1.54 and a 1-year high of $9.75. The firm has a 50 day simple moving average of $7.78 and a 200-day simple moving average of $4.98.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The business had revenue of $13.12 million for the quarter, compared to analysts’ expectations of $7.48 million. Nuvation Bio had a negative return on equity of 54.99% and a negative net margin of 813.07%. On average, equities analysts expect that Nuvation Bio will post -0.36 EPS for the current year.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.